Navigation Links
Johnson & Johnson Holds 2011 Annual Meeting of Shareholders
Date:4/28/2011

ple in it."

Better Treatments, Broader Reach

Weldon also emphasized the many opportunities the company has to make a difference in life-altering and life-threatening diseases that have not seen significant advancements in a number of years. In this category, he highlighted Alzheimer's disease, saying there was "an enormous unmet medical need in addressing this disease."  Weldon described the company's commitments and investments in helping to advance a promising new compound, bapineuzumab, which, he said, may have "the potential to actually address the underlying pathology of Alzheimer's disease."

Gorsky and McCoy discussed how the company is developing new innovations for many of the world's most pressing health needs, while also expanding its reach to serve a greater number of people around the world.

McCoy highlighted Consumer innovations including NICORETTE® QuickMist, recently launched in the U.K. and clinically proven to relieve nicotine cravings in as little as 60 seconds, and NEUTROGENA® Naturals, combining the benefits of natural ingredients with the effectiveness consumers expect from NEUTROGENA®.

In the company's Pharmaceuticals segment, McCoy described four innovative medicines that are currently in regulatory review in the United States and/or Europe – abiraterone acetate for advanced prostate cancer, telaprevir for Hepatitis C, rivaroxaban for preventing blood clots, and TMC 278 for HIV.

McCoy noted that the number of current U.S. regulatory submissions – seven – is exceptional, and that "these medicines represent transformational advances over the current standards of care for patients living with serious diseases."

The existing pharmaceuticals business, McCoy added, which began the year with a strong first quarter, was strengthened by the recent expansion of the Immunology portfolio as a result of the return of rights for REMICADE® and SIMPONI® i
'/>"/>

SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shareholders to Challenge Johnson & Johnsons Support for Left-Wing Policy Agenda: CEO William C. Weldon to Be Questioned on Firms Failure to Disclose Financial Information on Firms ObamaCare Lobbying It Pledged to Release Last Year
2. Johnson & Johnson and Synthes Announce Definitive Merger Agreement to Create Worlds Most Innovative and Comprehensive Orthopaedics Business
3. Perrigos PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
4. Johnson & Johnson Reports 2011 First-Quarter Results
5. Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
6. AFSCME Urges Shareholders to Vote against Executive Compensation at Pfizer (PFE) and Johnson & Johnson (JNJ)
7. Johnson & Johnson Announces Settlement With U.S. Department of Justice and U.S. Securities and Exchange Commission
8. Woman Files Suit in Beaumont, Texas Federal Court Against DePuy Orthopaedics and Johnson & Johnson Over Recalled Hip Device
9. Woman Files Suit in Federal Court Against DePuy Orthopaedics, Inc.,/Johnson & Johnson Over Recalled Hip Device
10. Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs
11. Johnson & Johnson to Participate in 2011 Citi Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015 Zimmer Holdings, Inc. ... today announced that its Board of Directors has approved the ... second quarter of 2015. The cash dividend of ... 14, 2015, to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:5/5/2015)... Silver Creek Pharmaceuticals, Inc. announced today the ... from the National Institute of Health (NIH). ... based biotechnology company that discovers and develops ... disease. This award will be used to advance their ... a heart attack. Silver Creek,s Smart Growth ...
(Date:5/5/2015)... 2015  Trovagene, Inc. (NASDAQ:  TROV), a developer ... results for the three months ended March 31, ... we presented favorable clinical results at ASCO GI, ... our Precision Cancer Monitoring platform,s ability to detect ... lung cancers," said Antonius Schuh, Ph.D., chief executive ...
Breaking Medicine Technology:Silver Creek Pharmaceuticals Awarded NIH SBIR Grant for Smart Growth Factor Technology 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6
... MORGANTOWN, W.Va., Jan. 11, 2011 A Blanchette ... the Journal of Neuroscience reveals underlying causes for ... identifies promising pharmaceutical solutions for the devastating condition ... the United States. The BRNI study is the ...
... Jan. 11, 2011 Hill-Rom Holdings, Inc. (NYSE: ... on Wednesday, January 26, 2011.  The company will host a ... 8 a.m. EST. Earnings Release:   Hill-Rom,s ... December 31, 2010, will be issued to the public after ...
Cached Medicine Technology:The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimer's Disease 2The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimer's Disease 3Hill-Rom Holdings, Inc. Hosts Fiscal 2011 First Quarter Earnings Webcast 2
(Date:5/6/2015)... CA (PRWEB) May 06, 2015 ... in an upcoming episode of Innovations with Ed ... 2015. Dates and show times TBA. , This ... dedicated to advancing tissue-based diagnostics. Audiences will learn ... IHC). Innovations will go behind the scenes to ...
(Date:5/6/2015)... 2015 When it comes to advice ... reputable and respected than those of a physician. It ... physician lose more weight than those who received no ... by the University of Georgia and published in the ... that patients advised by their physicians dropped more pounds, ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Healthcare marketing ... award and a silver award in the 2015 Aster ... care campaign and Ellis Medicine’s maternity campaign, respectively. The ... by healthcare organizations and marketing agencies. , The ... the service line — other/misc. category and hospital 150-200 ...
(Date:5/6/2015)... More and more people are finding success ... Flatt, personal trainer and nutritionist. This particular diet program has ... just three weeks or 21 days. , According to author ... and found to work on all types of people, regardless ... lose between 12 and 23 pounds using the diet, although ...
(Date:5/5/2015)... 06, 2015 Social Media Regulatory Affairs ... Media Your Most Powerful Marketing Tool and Get the ... http://www.fdanews.com/SocialMedia , Social media … Is it ... media’s reach. Patients are using it — learning about ... what they’ve discovered. , But, it can become a ...
Breaking Medicine News(10 mins):Health News:Novodiax to Be Featured in Upcoming Episode of Innovations TV Series 2Health News:Diet Doc Unveils New Protocol Around Doctor Advised Weight Loss 2Health News:Diet Doc Unveils New Protocol Around Doctor Advised Weight Loss 3Health News:Smith & Jones Wins in 2015 Aster Awards for Healthcare Marketing 2Health News:Brian Flatt Announces The 3 Week Diet - A Scientifically Proven Diet Plan 2Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 2Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 3Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 4
... ... problems, Sam’s Club is hosting free health screenings in more than 400 of its locations ... ... help its members and community residents detect a range of preventable health problems, Sam’s Club ...
... researcher is developing a novel therapy for Alzheimer,s disease ... builds up in the brain of an Alzheimer,s patientan ... and higher in effectiveness than current therapies. ... of Chemical, Biological and Mechanical Engineering, recently received a ...
... The Fogarty International Center of the National Institutes of ... an international AIDS training and research program based at ... countries most affected by the HIV/AIDS epidemic. The ... University and Tufts University since 1993 is part ...
... Donations ... ... -- Thousands of Haitian women and young girls living in temporary camps will sleep safer ... Idol viewers. More than $250,000 was raised for the United Nations Foundation ...
... ... acclaimed Anti-Phishing Phil online training game with updated graphics and content, as well as ... , ... 2010 -- Today Wombat Security Technologies announced it has released version 2.0 of its ...
... In 20 years, approximately 72 million older adults ... current number, according to the U.S. Administration on Aging. ... health care workers needed to provide elder care. As ... of Missouri researchers is refining electronic health record (EHR) ...
Cached Medicine News:Health News:Sam's Club Hosts Health Screenings July 10 2Health News:OU researcher developing novel therapy for Alzheimer's disease 2Health News:International AIDS training and research program awarded $3.6 million from NIH 2Health News:Haiti: United Nations Gets a Helping Hand from American Idol Viewers 2Health News:Haiti: United Nations Gets a Helping Hand from American Idol Viewers 3Health News:New Release of Wombat Security Technologies' Cyber Security Training Game: Anti-Phishing Phil 2Health News:Electronic health records prime clinicians to provide progressive care to older adults 2
The Midas II Stainer is an automated slide stainer designed for use in hematology and microbiology laboratories....
... an "assembly-line worker" for routine staining protocols ... Programmable continuous slide stainer for routine stains. ... in short time. Its large number of ... working principle provides a high throughput. A ...
Cholesterol, Total. An automated analyzer test kits....
Intended for the quantitative determination of total cholesterol in serum. Reaction: Endpoint. Reaction complete within five minutes. Wavelength: 500 nm. Linearity: 700 mg/dL (18.1 mmol/L). Single st...
Medicine Products: